Big data, mobile health and synthetic biology: An overview of some of the changes and measures were taken by regulators as they strive to keep up with the latest developments.
Habib Zalila and Emmanuelle Voisin
This article was published in Scrip Regulatory Affairs on 11 March 2015
Emmanuelle M. Voisin, Founder and CEO
Dr. Emmanuelle Voisin founded Voisin Consulting Life Sciences (VCLS) in 1997. The firm has become a leading advisor to Biotech, Pharma and Medtech manufacturers for the development, registration and launch of innovative medical technologies across international markets. Dr. Emmanuelle Voisin has 30 years’ experience in drug development. Her expertise lies in non-conventional development strategies, maximizing the use of regulatory mechanisms and innovative approaches to drug development, to bring innovative technologies to patients.
Habib Zalila, Senior Regulatory Scientist
He is Responsible for assisting international clients in the design and implementation of global regulatory strategies for drugs and biologics. He also Assists clients in the preparation/compilation of submission dossiers and in their interactions with Health Authorities.